



























![]()
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDT
Company Participants
Eric Rojas - VP & Head of Investor Relations
Adam Steensberg - President & CEO
David Kendall - Executive VP, Chief Medical Officer & Head of R&D
Henriette Wennicke - EVP & CFO
Conference Call Participants
Kirsty Ross-Stewart - BNP Paribas, Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division
Kelsey Lucerne
Benjamin Jackson - Jefferies LLC, Research Division
Alexandria Hammond - Wolfe Research, LLC
Xian Deng - UBS Investment Bank, Research Division
Charlie Haywood - BofA Securities, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Zealand Pharma Results for Q1 2026 Conference Call. [Operator Instructions] Please be advised that this conference is being recorded.
I would now like to hand the conference over to your speaker today, Eric Rojas, Vice President and Head of Investor Relations. Please go ahead.
Eric Rojas
VP & Head of Investor Relations
Thank you, operator, and thank you to everyone for joining us today to discuss Zealand Pharma's results for the first quarter of 2026. This is Eric Rojas, and I recently joined Zealand Pharma as Vice President and Head of Investor Relations. I'm pleased to be with the team today in Denmark to get the conference call started and look forward to working with all of you. The related company announcement for Q1 2026 is available on our website at zealandpharma.com.
As outlined on the slide, I would like to remind listeners that during today's call, we will be making forward-looking statements that are subject to risks and uncertainties. Turning to today's agenda. Joining me on this call is Adam Steensberg, President and Chief Executive Officer; Henriette Wennicke, Chief Financial Officer; and David Kendall, Chief Medical Officer. All speakers will be available for the Q&A session.
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。